Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Vandana Singh

BridgeBio Pharma Highlights Mid-Stage Study Data Of Acoramidis In Cardiomyopathy Trial

BridgeBio Pharma Inc (NASDAQ:BBIOannounced updated data from its ongoing Phase 2 open-label extension (OLE) study of acoramidis (AG10) in symptomatic transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM). 

  • Acoramidis was generally well-tolerated and resulted in sustained, near-complete TTR stabilization as measured by established ex vivo assays and increased serum TTR levels. 
  • Median N-terminal Pro-brain natriuretic peptide (NT-ProBNP) was stable or improving in trial participants throughout the OLE.
  • Serum TTR levels were sustainably increased from baseline, with mean concentration rising from 21.55 mg/dL at baseline to 30.06 mg/dL at Month 30 (+41%). 
  • Related: BridgeBio Pharma Posts Updated Data From Muscular Dystrophy Trial, Plots Path To Market.
  • Near-complete stabilization was verified with a mean stabilization of 102.5 ± 8.9% at Month 30.
  • Median NT-proBNP was stable or improving in study participants. At Month 30, the median change from baseline in NT-proBNP was -437 pg/mL. 
  • 68% of participants with available samples at Month 30 (15/22) had NT-proBNP levels below their baseline, suggesting an improvement in their heart failure severity
  • BridgeBio's Phase 3 study investigating acoramidis in ATTR-CM (ATTRibute-CM) is ongoing, with Month 30 topline data expected in mid-2023. 
  • In the Month 12 readout, no benefit of acoramidis relative to placebo was observed on the six-minute walk test. Still, improvements in the Kansas City Cardiomyopathy Questionnaire Overall Score, NT-proBNP, and serum TTR level were observed. 
  • Price Action: BBIO shares closed 6.90% higher at $10.85 on Friday
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.